中国·腾博-www.tengbo9885.com|官网首发

中文
中文

以患者需求为核心,驱动细胞免疫治疗创新,实现癌症可控化并最终治愈。

We strive to make patients-driven cellular immunotherapy innovation, to transform cancer into a manageable condition — and ultimately cure it.

2019
  • 0
Streamlined Low-Input Transcriptomics through EASY-RNAseq.     
J Mol Biol. 431(24):5075-5085. (PMID: 31491452)
Zhou Y., Xu H., Wu H., Yu H., Zhou P., Qiu X., Zheng Z., Chen Q., Xu F., Li G., Zhou J., Cheng G., He W., Zou L, Wan Y. (2019) 

 TCR repertoire and CDR3 motif analyses depict the role of αβ T cells in Ankylosing spondylitis.  
EBioMedicine. (19)30474-8. (*: Corresponding authors, PMCID: PMC6796593)
Zheng M., Zhang X., Zhou Y., Tang J., Han Q., Zhang Y., Ni Q., Chen G., Jia Q., Yu H., Liu S., Robins E., Jiang NJ., Wan Y.*, Li Q.-J. *, Chen Z.-N.*, Zhu P.* (2019)
03.23
2022
来源:
关键词:
相关阅读
关于腾博tengbo9885官网
研究与发展
产品及临床
新闻与媒体
XML 地图